𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prenatal screening for cystic fibrosis: an economic analysis

✍ Scribed by Randi Nielsen; Dorte Gyrd-Hansen

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
163 KB
Volume
11
Category
Article
ISSN
1057-9230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cystic fibrosis (CF) is the most common life‐shortening genetically transmitted disease in Denmark with a birth prevalence of 1 in 4700, resulting in 12–15 new cases of cystic fibroses annually.

The aim of this study is to disclose the societal resource implications of introducing a population wide prenatal screening programme for cystic fibrosis in Denmark. The present analysis is limited to the monetary consequences of introducing a screening programme, where costs of screening are compared to the potential benefits measured in cost savings involved if births of CF patients are avoided.

Screening costs in a Danish setting were estimated at DKK 2 771 262 (Β£231 438) per aborted affected fetus in the first screening round, stabilising at DKK 1 864 594 (Β£155 383) per aborted affected fetus at subsequent screening rounds. Comparing this figure with the estimated benefits of avoiding a CF case (DKK 2.1–4.4 million; Β£175 000–366 667) suggests that introducing a screening programme for cystic fibrosis will be net cost saving irrespective of the perspective of the analysis, assumptions on replacement children and method of estimating long‐term production gains/losses. Copyright Β© 2001 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

COUPLE-BASED PRENATAL SCREENING FOR CYST
COUPLE-BASED PRENATAL SCREENING FOR CYSTIC FIBROSIS IN PRIMARY CARE SETTINGS
✍ RICHARD A. DOHERTY; GLENN E. PALOMAKI; EDWARD M. KLOZA; JERYL L. ERICKSON; JAMES πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 617 KB

This study examines a couple-based screening protocol for cystic fibrosis (CF) during pregnancy. The screening test is positive only when both partners carry an identifiable mutation. The risk for the fetus to be homozygous is 1 in 4, and definitive prenatal diagnostic testing can be offered. Betwee

Cystic fibrosis screening recommended fo
Cystic fibrosis screening recommended for all women
πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 215 KB πŸ‘ 1 views

O bstetricians should offer all women cystic fibrosis (CF) screening, regardless of their ethnic background, the American Congress of Obstetricians and Gynecologists (ACOG) advises. An April ACOG Committee on Genetics opinion, published in the April issue of Obstetrics & Gynecology, suggests that o

Sweat testing following newborn screenin
Sweat testing following newborn screening for cystic fibrosis
✍ John Massie; Kevin Gaskin; Peter Van Asperen; Bridget Wilcken πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 1 views

Sweat testing remains the "gold standard" for the diagnosis of cystic fibrosis (CF) and is a critical component of newborn screening programs. We retrospectively reviewed sweat test results reported to a neonatal screening program for CF with respect to completeness of reported results and the value

Sweat analysis proficiency testing for c
Sweat analysis proficiency testing for cystic fibrosis
✍ Vicky A. LeGrys πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 33 KB πŸ‘ 1 views

The purpose of this report is to describe the College of American Pathologists sweat testing (SW) proficiency testing program for cystic fibrosis, to evaluate its impact on test performance, and to describe the current practice of sweat testing in North America. The study analyzed participant summar